At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia
In Brief
A Phase 2 clinical trial evaluating Furosemide Cohort 1, Furosemide Cohort 2, and 2 other interventions for Bronchopulmonary Dysplasia. Completed, enrolled 82 participants across 21 sites.
Detailed Summary
This study will describe the safety of furosemide in premature infants at risk of bronchopulmonary dysplasia and determine the preliminary effectiveness and pharmacokinetics (PK) of furosemide. Funding Source - FDA OOPD
Study Details
Timeline
Interventions
furosemide 1 mg/kg q 24 hours IV or 2 mg/kg q 24 hours enterally Cohorts will be enrolled sequentially after a safety review.
furosemide 1 mg/kg q 6 hours IV or 2 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
furosemide 2 mg/kg q 6 hours IV or 4 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
Sugar water will be administered in a equivalent volume as drug intervention.